The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Anthracycline Chemotherapy and Cardiotoxicity
Open accessAbstract
Anthracycline chemotherapy maintains a prominent role in treating many forms of cancer. Cardiotoxic side effects limit their dosing and improved cancer outcomes expose the cancer survivor to increased cardiovascular morbidity and mortality. The basic mechanisms of cardiotoxicity may involve direct pathways for reactive oxygen species generation and topoisomerase 2 as well as other indirect pathways. Cardioprotective treatments are few and those that have been examined include renin angiotensin system blockade, beta blockers, or the iron chelator dexrazoxane. New treatments exploiting the ErbB or other novel pro-survival pathways, such as conditioning, are on the cardioprotection horizon. Even in the forthcoming era of targeted cancer therapies, the substantial proportion of today's anthracycline-treated cancer patients may become tomorrow's cardiac patient.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Third Universal Definition of Myocardial Infarction
Thygesen, K., Alpert, J. S., Jaffe, A. S., Simoons, M. L., Chaitman, B. R., & White, H. D. (2012) · Circulation · doi:10.1161/cir.0b013e31826e1058 · Cited by 2,985
DNA Topoisomerases: Structure, Function, and Mechanism
Champoux, J. J. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.369 · Cited by 2,743
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw211 · Cited by 2,544
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,491
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
VON HOFF, D. D., LAYARD, M. W., BASA, P., DAVIS, H. L., VON HOFF, A. L., ROZENCWEIG, M., & MUGGIA, F. M. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-710 · Cited by 2,391
Cellular roles of DNA topoisomerases: a molecular perspective
Wang, J. C. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm831 · Cited by 2,353
Swain, S. M., Whaley, F. S., & Ewer, M. S. (2003) · Cancer · doi:10.1002/cncr.11407 · Cited by 2,313
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011573 · Cited by 2,019
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
Zhang, S., Liu, X., Bawa-Khalfe, T., Lu, L.-S., Lyu, Y. L., Liu, L. F., & Yeh, E. T. H. (2012) · Nature Medicine · doi:10.1038/nm.2919 · Cited by 1,948
Doxorubicin-Induced Cardiomyopathy
Singal, P. K., & Iliskovic, N. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809243391307 · Cited by 1,845
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.654 · Cited by 1,795
Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy
Cardinale, D., Colombo, A., Bacchiani, G., Tedeschi, I., Meroni, C. A., Veglia, F., Civelli, M., Lamantia, G., Colombo, N., Curigliano, G., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.013777 · Cited by 1,733
Underlying Causes and Long-Term Survival in Patients with Initially Unexplained Cardiomyopathy
Felker, G. M., Thompson, R. E., Hare, J. M., Hruban, R. H., Clemetson, D. E., Howard, D. L., Baughman, K. L., & Kasper, E. K. (2000) · New England Journal of Medicine · doi:10.1056/nejm200004133421502 · Cited by 1,723
Adriamycin-Induced DNA Damage Mediated by Mammalian DNA Topoisomerase II
Tewey, K. M., Rowe, T. C., Yang, L., Halligan, B. D., & Liu, L. F. (1984) · Science · doi:10.1126/science.6093249 · Cited by 1,538
Przyklenk, K., Bauer, B., Ovize, M., Kloner, R. A., & Whittaker, P. (1993) · Circulation · doi:10.1161/01.cir.87.3.893 · Cited by 1,379
Coleman, M., Forman, D., Bryant, H., Butler, J., Rachet, B., Maringe, C., Nur, U., Tracey, E., Coory, M., Hatcher, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62231-3 · Cited by 1,114
Anthracycline-Induced Cardiomyopathy
Cardinale, D., Colombo, A., Lamantia, G., Colombo, N., Civelli, M., De Giacomi, G., Rubino, M., Veglia, F., Fiorentini, C., & Cipolla, C. M. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.03.095 · Cited by 1,105
Cardinale, D., Colombo, A., Sandri, M. T., Lamantia, G., Colombo, N., Civelli, M., Martinelli, G., Veglia, F., Fiorentini, C., & Cipolla, C. M. (2006) · Circulation · doi:10.1161/circulationaha.106.635144 · Cited by 1,026
Cardinale, D., Sandri, M. T., Colombo, A., Colombo, N., Boeri, M., Lamantia, G., Civelli, M., Peccatori, F., Martinelli, G., Fiorentini, C., et al. (2004) · Circulation · doi:10.1161/01.cir.0000130926.51766.cc · Cited by 955
ErbB2 is essential in the prevention of dilated cardiomyopathy
Crone, S. A., Zhao, Y.-Y., Fan, L., Gu, Y., Minamisawa, S., Liu, Y., Peterson, K. L., Chen, J., Kahn, R., Condorelli, G., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-459 · Cited by 903
Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation
Ichikawa, Y., Ghanefar, M., Bayeva, M., Wu, R., Khechaduri, A., Prasad, S. V. N., Mutharasan, R. K., Naik, T. J., & Ardehali, H. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72931 · Cited by 878
Patnaik, J. L., Byers, T., DiGuiseppi, C., Dabelea, D., & Denberg, T. D. (2011) · Breast Cancer Research · doi:10.1186/bcr2901 · Cited by 872
Lipshultz, S. E., Lipsitz, S. R., Mone, S. M., Goorin, A. M., Sallan, S. E., Sanders, S. P., Orav, E. J., Gelber, R. D., & Colan, S. D. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506293322602 · Cited by 803
Staal, S. P. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.14.5034 · Cited by 767
Smith, L. A., Cornelius, V. R., Plummer, C. J., Levitt, G., Verrill, M., Canney, P., & Jones, A. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-337 · Cited by 753
Modifiable Risk Factors and Major Cardiac Events Among Adult Survivors of Childhood Cancer
Armstrong, G. T., Oeffinger, K. C., Chen, Y., Kawashima, T., Yasui, Y., Leisenring, W., Stovall, M., Chow, E. J., Sklar, C. A., Mulrooney, D. A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.3205 · Cited by 734
Mertens, A. C., Liu, Q., Neglia, J. P., Wasilewski, K., Leisenring, W., Armstrong, G. T., Robison, L. L., & Yasui, Y. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn310 · Cited by 730
Lipshultz, S. E., Lipsitz, S. R., Sallan, S. E., Dalton, V. M., Mone, S. M., Gelber, R. D., & Colan, S. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.121 · Cited by 727
Thavendiranathan, P., Grant, A. D., Negishi, T., Plana, J. C., Popović, Z. B., & Marwick, T. H. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.09.035 · Cited by 689
Gulati, G., Heck, S. L., Ree, A. H., Hoffmann, P., Schulz-Menger, J., Fagerland, M. W., Gravdehaug, B., von Knobelsdorff-Brenkenhoff, F., Bratland, Å., Storås, T. H., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw022 · Cited by 687
Bosch, X., Rovira, M., Sitges, M., Domènech, A., Ortiz-Pérez, J. T., de Caralt, T. M., Morales-Ruiz, M., Perea, R. J., Monzó, M., & Esteve, J. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.072 · Cited by 632
Davies, K. J., & Doroshow, J. H. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35746-0 · Cited by 631
Lipshultz, S. E., Rifai, N., Dalton, V. M., Levy, D. E., Silverman, L. B., Lipsitz, S. R., Colan, S. D., Asselin, B. L., Barr, R. D., Clavell, L. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035153 · Cited by 623
Lyu, Y. L., Kerrigan, J. E., Lin, C.-P., Azarova, A. M., Tsai, Y.-C., Ban, Y., & Liu, L. F. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1649 · Cited by 612
Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer
Armstrong, G. T., Chen, Y., Yasui, Y., Leisenring, W., Gibson, T. M., Mertens, A. C., Stovall, M., Oeffinger, K. C., Bhatia, S., Krull, K. R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1510795 · Cited by 568
Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy
Cardinale, D., Sandri, M. T., Martinoni, A., Tricca LabTech, A., Civelli, M., Lamantia, G., Cinieri, S., Martinelli, G., Cipolla, C. M., & Fiorentini, C. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00748-8 · Cited by 551
Third Universal Definition of Myocardial Infarction
Thygesen, K., Alpert, J. S., Jaffe, A. S., Simoons, M. L., Chaitman, B. R., White, H. D., & For the Universal Definition of MI, W. G. J. E. (2012) · Global Heart · doi:10.1016/j.gheart.2012.08.001 · Cited by 544
Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis.
Arola, O., Saraste, A., Pulkki, K. J., Kallajoki, M. A., Parvinen, M., & Voipio-Pulkki, L. M. (2000) · PubMed · Cited by 494
Lipshultz, S. E., Scully, R. E., Lipsitz, S. R., Sallan, S. E., Silverman, L. B., Miller, T. L., Barry, E. V., Asselin, B. L., Athale, U., Clavell, L. A., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70204-7 · Cited by 446
Cardiopulmonary Function and Age-Related Decline Across the Breast Cancer Survivorship Continuum
Jones, L. W., Courneya, K. S., Mackey, J. R., Muss, H. B., Pituskin, E. N., Scott, J. M., Hornsby, W. E., Coan, A. D., Herndon, J. E., Douglas, P. S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.9014 · Cited by 442
Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera
Landolfi, R., Di Gennaro, L., Barbui, T., De Stefano, V., Finazzi, G., Marfisi, R., Tognoni, G., Marchioli, R., & for the European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP) (2007) · Blood · doi:10.1182/blood-2006-08-042515 · Cited by 416
Adriamycin-induced oxidative mitochondrial cardiotoxicity
Berthiaume, J. M., & Wallace, K. B. (2007) · Cell Biology and Toxicology · doi:10.1007/s10565-006-0140-y · Cited by 409
Cardiotoxicity of anticancer treatments: what the cardiologist needs to know
Ewer, M. S., & Ewer, S. M. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.121 · Cited by 373
Subclinical Late Cardiomyopathy After Doxorubicin Therapy for Lymphoma in Adults
Hequet, O., Le, Q. H., Moullet, I., Pauli, E., Salles, G., Espinouse, D., Dumontet, C., Thieblemont, C., Arnaud, P., Antal, D., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.033 · Cited by 340
Seicean, S., Seicean, A., Plana, J. C., Budd, G. T., & Marwick, T. H. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.067 · Cited by 326
Kaya, M. G., Ozkan, M., Gunebakmaz, O., Akkaya, H., Kaya, E. G., Akpek, M., Kalay, N., Dikilitas, M., Yarlioglues, M., Karaca, H., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.06.023 · Cited by 325
Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy
Cardinale, D., Sandri, M. T., Martinoni, A., Borghini, E., Civelli, M., Lamantia, G., Cinieri, S., Martinelli, G., Fiorentini, C., & Cipolla, C. M. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf170 · Cited by 313
Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer.
Ryberg, M., Nielsen, D., Skovsgaard, T., Hansen, J., Jensen, B. V., & Dombernowsky, P. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.11.3502 · Cited by 289
Sloth, A. D., Schmidt, M. R., Munk, K., Kharbanda, R. K., Redington, A. N., Schmidt, M., Pedersen, L., Sørensen, H. T., Bøtker, H. E., & CONDI Investigators (2014) · European Heart Journal · doi:10.1093/eurheartj/eht369 · Cited by 287
Finck, B. N., & Kelly, D. P. (2007) · Circulation · doi:10.1161/circulationaha.107.670588 · Cited by 282
Cancer Therapy–Induced Cardiotoxicity: Basic Mechanisms and Potential Cardioprotective Therapies
Hahn, V. S., Lenihan, D. J., & Ky, B. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.113.000665 · Cited by 264
Efficiency of Atorvastatin in the Protection of Anthracycline-Induced Cardiomyopathy
Acar, Z., Kale, A., Turgut, M., Demircan, S., Durna, K., Demir, S., Meriç, M., & Ağaç, M. T. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.05.025 · Cited by 255
White, S. K., Frohlich, G. M., Sado, D. M., Maestrini, V., Fontana, M., Treibel, T. A., Tehrani, S., Flett, A. S., Meier, P., Ariti, C., et al. (2015) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2014.05.015 · Cited by 238
Self-citationCoexistence of Pregnancy and Malignancy
Pavlidis, N. A. (2002) · The Oncologist · doi:10.1634/theoncologist.7-6-573 · Cited by 227
Huang, C., Zhang, X., Ramil, J. M., Rikka, S., Kim, L., Lee, Y., Gude, N. A., Thistlethwaite, P. A., Sussman, M. A., Gottlieb, R. A., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.902221 · Cited by 203
Hu, Y.-F., Liu, C.-J., Chang, P. M.-H., Tsao, H.-M., Lin, Y.-J., Chang, S.-L., Lo, L.-W., Tuan, T.-C., Li, C.-H., Chao, T.-F., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.08.036 · Cited by 198
The treatment of Hodgkin's and non-Hodgkin's lymphoma in pregnancy
Pereg, D., Koren, G., & Lishner, M. (2007) · Haematologica · doi:10.3324/haematol.11097 · Cited by 195
Decline in the Use of Anthracyclines for Breast Cancer
Giordano, S. H., Lin, Y.-L., Kuo, Y. F., Hortobagyi, G. N., & Goodwin, J. S. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.1273 · Cited by 192
Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes
Lipshultz, S. E., Miller, T. L., Lipsitz, S. R., Neuberg, D. S., Dahlberg, S. E., Colan, S. D., Silverman, L. B., Henkel, J. M., Franco, V. I., Cushman, L. L., et al. (2012) · Pediatrics · doi:10.1542/peds.2012-0727 · Cited by 175
cTnT can be a useful marker for early detection of anthracycline cardiotoxicity
Kilickap, S., Barista, I., Akgul, E., Aytemir, K., Aksoyek, S., Aksoy, S., Celik, I., Kes, S., & Tekuzman, G. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi152 · Cited by 167
Davies, W. R., Brown, A. J., Watson, W., McCormick, L. M., West, N. E. J., Dutka, D. P., & Hoole, S. P. (2013) · Circulation: Cardiovascular Interventions · doi:10.1161/circinterventions.112.000184 · Cited by 162
Wadugu, B. A., & Kühn, B. (2012) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00063.2012 · Cited by 153
Carpenter, A. J., & Porter, A. C. G. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-08-0732 · Cited by 139
Ma, J., Wang, Y., Zheng, D., Meng, W., Xu, H., & Peng, T. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs309 · Cited by 132
Sandri, M. T., Cardinale, D. M., Zorzino, L., Passerini, R., Lentati, P., Martinoni, A., Martinelli, G., & Cipolla, C. M. (2003) · Clinical Chemistry · doi:10.1373/49.2.248 · Cited by 123
The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin
Hasinoff, B. B., Patel, D., & Wu, X. (2003) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2003.08.005 · Cited by 115
Iarussi, D., Auricchio, U., Agretto, A., Murano, A., Giuliano, M., Casale, F., Indolfi, P., & Iacono, A. (1994) · Molecular Aspects of Medicine · doi:10.1016/0098-2997(94)90030-2 · Cited by 114
Sarosiek, K. A., & Letai, A. G. (2016) · FEBS Journal · doi:10.1111/febs.13714 · Cited by 113
El‐Shitany, N. A., Tolba, O., El-Shanshory, M. R., & Elhawary, E. E. (2012) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2012.06.416 · Cited by 109
Co-dependence of the neural and humoral pathways in the mechanism of remote ischemic conditioning
Pickard, J., Davidson, S., Hausenloy, D., & Yellon, D. (2016) · Basic Research in Cardiology · doi:10.1007/s00395-016-0568-z · Cited by 107
Self-citationCardiovascular morbidity in long‐term survivors of early‐onset cancer: A population‐based study
Kero, A. E., Järvelä, L. S., Arola, M. O., Malila, N. K., Madanat‐Harjuoja, L. M., Matomäki, J., & Lähteenmäki, P. M. (2013) · International Journal of Cancer · doi:10.1002/ijc.28385 · Cited by 91
Concentrations of doxorubicin and its metabolites in human autopsy heart and other tissues.
Stewart, D. J., Grewaal, D. S., Green, R. M., Mikhael, N. Z., Goel, R., Montpetit, V., & Redmond, M. D. (1994) · PubMed · Cited by 87
The Damaging Potential of Leukocyte Activation in the Microcirculation
Schmid‐Schönbein, G. W. (1993) · Angiology · doi:10.1177/000331979304400108 · Cited by 86
Management strategies and outcomes for very elderly patients with diffuse large B‐cell lymphoma
Chihara, D., Westin, J. R., Oki, Y., Ahmed, M. A., Do, B., Fayad, L., Hagemeister, F. B., Romaguera, J. E., Fanale, M. A., Lee, H. J., et al. (2016) · Cancer · doi:10.1002/cncr.30173 · Cited by 80
Schupp, N., Schmid, U., Heidland, A., & Stopper, H. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.11.016 · Cited by 78
Amifostine protection against doxorubicin cardiotoxicity in rats
Dragojevic-Simic, V. M., Dobrić, S., Bokonjić, D., Vučinić, Ž., Sinovec, S. M., Jacevic, V. M., & Dogovic, N. P. (2004) · Anti-Cancer Drugs · doi:10.1097/00001813-200402000-00011 · Cited by 58
Deferiprone Does Not Protect against Chronic Anthracycline Cardiotoxicity in Vivo
Popelová, O., Štěrba, M., Šimůnek, T., Mazurová, Y., Němečková, I., Hroch, M., Adamcová, M., & Geršl, V. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.137604 · Cited by 53
Ahmed, A., Blonde, K., Hackam, D., et al. (2014) · Annals of Medicine · doi:10.3109/07853890.2014.959558 · Cited by 50
Prognostic Comparison of Different Sensitivity Cardiac Troponin Assays in Stable Heart Failure
Grodin, J. L., Neale, S., Wu, Y., Hazen, S. L., & Tang, W. H. W. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.09.029 · Cited by 44
Yiu, K., Lau, K. K., Zhao, C., Chan, Y., Chen, Y., Zhen, Z., Wong, A., Lau, C., & Tse, H. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-63 · Cited by 43
Katsurada, K., Ichida, M., SAKURAGI, M., Takehara, M., Hozumi, Y., & Kario, K. (2014) · SpringerPlus · doi:10.1186/2193-1801-3-620 · Cited by 41
Amelioration of doxorubicin-induced cardiotoxicity by deferiprone in rats
Ammar, E. M., Said, S. A., Suddek, G. M., & El-Damarawy, S. L. (2011) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y11-020 · Cited by 36
Chung, R., Maulik, A., Hamarneh, A., Hochhauser, D., Hausenloy, D. J., Walker, J. M., & Yellon, D. M. (2016) · Clinical Cardiology · doi:10.1002/clc.22507 · Cited by 29
Self-citationKuster, N., Monnier, K., Baptista, G., Dupuy, A., Badiou, S., Bargnoux, A., Jeandel, C., & Cristol, J. (2014) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2014-0121 · Cited by 28
Rimal, H., Lee, S.-W., Lee, J.-H., & Oh, T. (2015) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2015.08.019 · Cited by 27
Hochholzer, W., Valina, C. M., Stratz, C., Amann, M., Schlittenhardt, D., Büttner, H. J., Trenk, D., & Neumann, F. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.07.094 · Cited by 24
Grinstein, J., Bonaca, M. P., Jarolím, P., Conrad, M. J., Bohula, E. A., Deenadayalu, N., Braunwald, E., Giugliano, R. P., Newby, L. K., Sabatine, M. S., et al. (2015) · Clinical Cardiology · doi:10.1002/clc.22379 · Cited by 19
Cited by
Mehta, L. S., Watson, K. E., Barac, A., Beckie, T. M., Bittner, V., Cruz-Flores, S., Dent, S., Kondapalli, L., Ky, B., Okwuosa, T., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000556 · Cited by 848
Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity
Avila, M. S., Ayub-Ferreira, S. M., de Barros Wanderley, M. R., das Dores Cruz, F., Gonçalves Brandão, S. M., Rigaud, V. O. C., Higuchi-dos-Santos, M. H., Hajjar, L. A., Kalil Filho, R., Hoff, P. M., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.049 · Cited by 507
Plant-Derived Anticancer Compounds as New Perspectives in Drug Discovery and Alternative Therapy
Dehelean, C. A., Marcovici, I., Soica, C., Mioc, M., Coricovac, D., Iurciuc, S., Cretu, O. M., & Pinzaru, I. (2021) · Molecules · doi:10.3390/molecules26041109 · Cited by 502
Topoisomerases as anticancer targets
Delgado, J. L., Hsieh, C.-M., Chan, N.-L., & Hiasa, H. (2018) · Biochemical Journal · doi:10.1042/bcj20160583 · Cited by 481
Delost, M. D., Smith, D. T., Anderson, B. J., & Njardarson, J. T. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00876 · Cited by 409
Metadata
- Authors
- McGowan, J. V., Chung, R., Maulik, A., Piotrowska, I., Walker, J. M., & Yellon, D. M.
- Venue
- Cardiovascular Drugs and Therapy
- Published
- 2017-02
- Volume
- 31
- Issue
- 1
- Pages
- 63-75
- ISSN
- 0920-3206 (ISSN-L)
- 1573-7241
- OpenAlex
- W2586749137
- Cited by
- 956
- References
- 88
- FWCI
- 54.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.